Your browser doesn't support javascript.
loading
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Paz-Ares, L; Tan, E-H; O'Byrne, K; Zhang, L; Hirsh, V; Boyer, M; Yang, J C-H; Mok, T; Lee, K H; Lu, S; Shi, Y; Lee, D H; Laskin, J; Kim, D-W; Laurie, S A; Kölbeck, K; Fan, J; Dodd, N; Märten, A; Park, K.
Afiliação
  • Paz-Ares L; Medical Oncology Department, Hospital Universitario Doce de Octubre, Universidad Complutense and CNIO, Madrid, Spain.
  • Tan EH; Division of Medical Oncology, National Cancer Centre, Singapore.
  • O'Byrne K; Cancer Section, Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Australia.
  • Zhang L; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Hirsh V; Department of Oncology, McGill University, Montreal, Canada.
  • Boyer M; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia.
  • Yang JC; Department of Oncology, National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan.
  • Mok T; Department of Clinical Oncology, State Key Laboratory of South China, The Chinese University of Hong Kong, Hong Kong.
  • Lee KH; Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Chungbuk, South Korea.
  • Lu S; Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai.
  • Shi Y; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Lee DH; Department of Oncology, Asan Medical Center, Seoul, South Korea.
  • Laskin J; Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
  • Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Laurie SA; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada.
  • Kölbeck K; Pulmonary Diseases, Karolinska University Hospital, Solna, Stockholm, Sweden.
  • Fan J; Clinical Program Leader, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, USA.
  • Dodd N; Biostatistics, Boehringer Ingelheim Ltd UK, Bracknell, UK.
  • Märten A; TA Oncology, Boehringer Ingelheim GmbH, Ingelheim, Germany.
  • Park K; Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Ann Oncol ; 28(2): 270-277, 2017 02 01.
Article em En | MEDLINE | ID: mdl-28426106
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinazolinas / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Antineoplásicos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinazolinas / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Antineoplásicos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article